Apollo Health Ventures is a transatlantic early-stage venture capital firm that co-founds and invests in transformative healthcare and biotechnology companies targeting age-related diseases and aging. The firm operates from offices in Berlin, Luxembourg, and Boston.
54% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (1 deals in the last 12 months vs 3 prior). Their most common stage is seed (54% of deals). Average disclosed round size is $53.0M (across 11 rounds with reported amounts).
Portfolio
13
Fund Size
$180M
Top Stage
Seed
Last 12 Mo
1
Team
NR
Nils Regge
Co-Founder & General Partner
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
13 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Scripta Therapeutics | Seed | $12M | Nov 2025 |
| TTherini Bio | Series A | $39M | May 2025 |
| RRefoxy Pharmaceuticals | Seed | $10M | Dec 2024 |
 Booster Therapeutics | Seed | $15M | Oct 2024 |
 Aeovian Pharmaceuticals | Unknown | $50M | Mar 2024 |
 Refoxy Pharma | Seed | — | Jan 2024 |
 Auron Therapeutics | Series A | $48M | Jul 2022 |
 Scripta | Seed | $12M | — |
| BBionyra | Series A | $165M | — |
 Haya Therapeutics | Series A | $65M | — |
| RRefoxy Pharma | Seed | — | — |
 Bionyra Pharma | Series A | $165M | — |
| CCleara | Seed | $2.5M | — |
Top Co-Investors
Sofinnova Partners4 shared
Arkin Bio Ventures3 shared
Eli Lilly and Company3 shared
Sanofi Ventures3 shared
High-Tech Gründerfonds3 shared
YZR Capital2 shared
Parkwalk Advisors2 shared
Oxford Science Enterprises2 shared
AlbionVC2 shared
VIVES Partners2 shared
Jeito Capital2 shared
Sixty Degree Capital2 shared
Casdin Capital1 shared
DCVC1 shared
Qiming Venture Partners USA1 shared
BrightEdge1 shared
Mubadala Ventures1 shared
Polaris Partners1 shared
Novo Holdings A/S1 shared
Last updated: 9 September 2026